Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 578

Results For "NAL"

5920 News Found

Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years
News | June 14, 2021

Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years

The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination


Lupin donates Oxygen generation plants in Mah, MP & Gujarat
News | June 12, 2021

Lupin donates Oxygen generation plants in Mah, MP & Gujarat

These five oxygen plants with a total capacity of 3,840 cubic meters of oxygen per day have been donated to Madhya Pradesh, Maharashtra, and Gujarat


IPCA Laboratories increases stake in Trophic Wellness to 52.35%
News | June 12, 2021

IPCA Laboratories increases stake in Trophic Wellness to 52.35%

With the acquisition of these further shares, TWPL has now become company's subsidiary.


India aims to vaccinate 1 crore people every day
News | June 12, 2021

India aims to vaccinate 1 crore people every day

India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021


Alkem launches Perampil tablets at affordable prices
News | June 11, 2021

Alkem launches Perampil tablets at affordable prices

The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access


CSIR join hands with SUVEN Pharmaceuticals
Drug Approval | June 11, 2021

CSIR join hands with SUVEN Pharmaceuticals

The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL


'We plan to invest Rs. 1,000 Cr in the next 3 to 4 years.' Priyanka Chigurupati, Executive Director, Granules Pharmaceutical Inc.
Interviews | June 10, 2021

'We plan to invest Rs. 1,000 Cr in the next 3 to 4 years.' Priyanka Chigurupati, Executive Director, Granules Pharmaceutical Inc.

In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:


Glenmark's interim data from PMS Study on Favipiravir released
News | June 09, 2021

Glenmark's interim data from PMS Study on Favipiravir released

The study was conducted in patients with mild to moderate COVID-19


Lupin launches Digital Asthma Educator platform
News | June 08, 2021

Lupin launches Digital Asthma Educator platform

The new platform is the latest initiative under Lupin’s long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailment


Lupin receives U.S. FDA approval for HIV-1 drug
Pharma | June 08, 2021

Lupin receives U.S. FDA approval for HIV-1 drug

Emtricitabine and Tenofovir Disoproxil Fumarate tablets had estimated annual sales of US $2.1 billion in the U.S. according to IQVIA MAT March 2021